Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.

"Declarations Consent for publicationAll authors have read the manuscript and made the decision to submit it for publication. The corresponding author had final responsibility for the decision to submit for publication. Competing interestsThis trial was designed through collaboration between the investigators and Qilu Pharmaceutical Co., Ltd., the manufacturer of generic pomalidomide in Jinan, China. The study's design was a joint effort between the sponsor and the study committee. Wenming Chen, Juan Li, Huixing Zhou, Yafei Wang, Jiao Chen, Aili He, Jie Jin, Quanyi Lu, Ying Zhao, Junjun Li, Ming Hou, Liping Su, Xun Lai, Wei Wang, Lihong Liu, Yanping Ma, Da Gao, Wenhong Lai, Xin Zhou, Hongmei Jing, Jinqiao Zhang, Wei Yang, Xuehong Ran, Congmeng Lin, Jianping Hao, Taiwu Xiao, Zhenqian Huang, Zhigang Zhu, Qing Wang, Baijun Fang, Binghua Wang, Yanping Song, and Zhen Cai received research funding from Qilu Pharmaceutical Co. Ltd. Moreover, Bo Liu, Yanan Zhu, Xinai Yang, and Xiaoyan Kang were employees of Qilu Pharmaceutical Co. Ltd. All authors declare that they have no other competing interests. Competing interests This trial was designed through collaboration between the investigators and Qilu Pharmaceutical Co., Ltd., the manufacturer of generic pomalidomide in Jinan, China. The study's design was a joint effort between the sponsor and the study committee. Wenming Chen, Juan Li, Huixing Zhou, Yafei Wang, Jiao Chen, Aili He, Jie Jin, Quanyi Lu, Ying Zhao, Junjun Li, Ming Hou, Liping Su, Xun Lai, Wei Wang, Lihong Liu, Yanping Ma, Da Gao, Wenhong Lai, Xin Zhou, Hongmei Jing, Jinqiao Zhang, Wei Yang, Xuehong Ran, Congmeng Lin, Jianping Hao, Taiwu Xiao, Zhenqian Huang, Zhigang Zhu, Qing Wang, Baijun Fang, Binghua Wang, Yanping Song, and Zhen Cai received research funding from Qilu Pharmaceutical Co. Ltd. Moreover, Bo Liu, Yanan Zhu, Xinai Yang, and Xiaoyan Kang were employees of Qilu Pharmaceutical Co. Ltd. All authors declare that they have no other competing interests."

"Funding The trial was designed by the investigators in collaboration with the manufacturer of generic pomalidomide (Qilu Pharmaceutical Co. Ltd., Shandong, China). The study design was decided by the sponsor in collaboration with the study steering committee."

"Registration number ClinicalTrials.gov NCT05236621, retrospectively registered on February 11, 2022."